OpenAI introduced GPT-Rosalind, an AI model designed to support pharmaceutical development and research. The model aims to strengthen early-phase research and potentially help reduce the traditional 10–15 year U.S. drug approval timeline. Read more about pharmacy market news in our Weekly Dose newsletter!
